#Mr.Abhishek Singh (ceo Taj

[asiainfomed-blog]

Global Naltrexone HCL Market- Sun Pharma, Sanofi, Rusan, Noramco, IVAX,

Market.Biz Leading Research Firm has added latest report on "Global Naltrexone HCL Market by Manufacturers, Regions, Type and Application, Forecast to 2021".

Socorro Barner

-January 10, 2017

Share on Facebook

Tweet on Twitter

The Naltrexone HCL market report covers forecast and analysis for the Naltrexone HCL market on a global and regional level. The Naltrexone HCL industry report provides historic data of 2015 along with a Naltrexone HCL market forecast from 2015 to 2021 based on Naltrexone HCL industry volume and Naltrexone HCL revenue (USD Million). The Naltrexone HCL includes drivers and restraints for the Naltrexone HCL market along with the impact they have on the demand over the forecast period. Additionally, the Naltrexone HCL market report includes the study of opportunities available in the Naltrexone HCL market on a global level.

The Naltrexone HCL market report discusses in details about the vendor landscape of the Naltrexone HCL market. The Naltrexone HCL Industry has been analyzed on the basis of Naltrexone HCL market attractiveness and investment feasibility. The Naltrexone HCL report lists the key players in the Naltrexone HCL market and provides crucial information about them such as business overview, revenue segmentation, and product offerings. Through SWOT analysis, the Naltrexone HCL industry report analyses the Naltrexone HCL market growth of the key players during the forecast horizon.

In Naltrexone HCL Market report, all the segments have been analyzed based on present and Naltrexone HCL market future trends and the Naltrexone HCL market is estimated from 2015 to 2021. In this Naltrexone HCL report, regional segmentation covers the Naltrexone HCL industry current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Do Inquiry Before Accessing Report Here: https://market.biz/report/global-naltrexone-hcl-market-gir/29696/#inquiry

This report segments the global Naltrexone HCL industry as follows:

Global Naltrexone HCL Market: Manufacturers Segment Analysis 1. Taj Pharmaceuticals 2. Sun Pharma 3. Sanofi 4. Rusan 5. Noramco 6. IVAX 7. Haida Taicheng 8. Freedom Pharmaceuticals 9. Faran Shimi

Global Naltrexone HCL Market: Applications Segment Analysis 1. Opioid Independence 2. Alcohol Independence 3. Other

Global Naltrexone HCL Market: Regional Segment Analysis 1. North America (USA, Canada and Mexico) 2. Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 3. Europe (Germany, France, UK, Russia and Italy) 4. South America, Middle East and Africa

Get Instant Access To the Full Report with TOC at: https://market.biz/report/global-naltrexone-hcl-market-gir/29696/

Report on (Global study on Naltrexone HCL industry) mainly covers 13 Chapters to deeply display the global Naltrexone HCL market.

Chapter I, to explain Naltrexone HCL market Intro, product extent, market summary, market opportunities, market threat, market driving force;

Chapter II, to examine the top manufacturers of Naltrexone HCL market, with sales, revenue, as well as price of Naltrexone HCL, in 2015 and also 2016;

Chapter III, to display the Naltrexone HCL market’s affordable circumstance amongst the top key players, with sales, Naltrexone HCL market revenue and share in 2015 and also 2016;

Chapter IV, to reveal the worldwide Naltrexone HCL market by areas, with sales, revenue and market share of Naltrexone HCL, for each region, from 2011 to 2016;

Chapter V, VI, VII & VIII, to analyze the key regions of Naltrexone HCL market, with sales, revenue and also market share by manufacturers countries in these regions;

Chapter IX and X, to reveal the Naltrexone HCL market by type as well as application, with sales Naltrexone HCL market share as well as growth price by type, application, from 2011 to 2016;

Chapter XI, Global Naltrexone HCL market forecast, by regions, type and also application, with sales as well as revenue, from 2016 to 2021;

Chapter XII and also XIII, to describe Naltrexone HCL market sales network, suppliers, investors, suppliers, appendix and also data resource.

Browse More Related Category Research Reports at: https://market.biz/reporttype/pharmaceuticals-and-healthcare/

TAGS

Global Naltrexone HCL Market

SHARE

Facebook

Twitter

[thetajpharmaceooffice]

“In my house, education was the paramount value. And if you grew up in a neighborhood like mine, you were forced to decide early on what you stood for in life, because there were a lot of peer pressures that could take you the wrong way.”

Mr.Abhishek Kumar Singh, CEO, Taj Pharma Group - Mumbai.

[thoughtfulenthusiastgoatee-blog]

Global Ketoprofen Market-Taj Pharmaceuticals (India), Century Pharmaceuticals (India), BEC Chemicals (India)Press release from: Market News Ketoprofen, (RS)2-(3-benzoylphenyl)-propionic acid (chemical formula C16H14O3) is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body’s production of prostaglandin.

Major players in the global Ketoprofen market :- Taj Pharmaceuticals (India) Century Pharmaceuticals (India) BEC Chemicals (India) Zhejiang Jiuzhou (China) Request for sample @ goo.gl/iD81q5 This report provides detailed analysis of worldwide markets for Ketoprofen from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and sub sectors. It covers the key technological and market trends in the Ketoprofen market and further lays out an analysis of the factors influencing the supply/demand for Ketoprofen, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies. Global Ketoprofen Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Ketoprofen market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. Browe full report With TOC: marketinsights.biz/global-ketoprofen-market-outlook-2016-... The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Ketoprofen industry has been provided. "MarketInsights.Biz” offer reports from top publishers and update to serve you with immediate on-line access to professional insights on global industries, companies, products, and trends. Customers can buys different reports across various categories such as Chemical and Material, Biotechnology, Healthcare, Food and beverages, Automobile and various sectors. Our Website offers safe and secure online ordering experience, convenient payment options. Contact US: Frank Valadez Director of Business Development Website: marketinsights.biz/ Email:sales@marketinsights.biz This release was published on openPR.

[asiainfomed-blog]

Check out "Love Vs Ego .......... Story A STORY FROM ABHISHEK KUMAR SINGH CEO TAJ PHARMA INDIA (MUMBAI)" on edocr.

[asiainfomed-blog]

Check out "Enjoy your life at every moment.... A STORY FROM ABHISHEK KUMAR SINGH CEO TAJ PHARMA INDIA (MUMBAI)" on edocr.

[asiainfomed-blog]

Check out "“Act of Kindness and Goodwill”- SHORT STORY Abhishek k singh Ceo Taj Pharmaceuticals" on edocr.

[asiainfomed-blog]

Check out "TAJ PHARMA " on edocr.

[asiainfomed-blog]

Check out "Taj Pharma Mumbai" on edocr.

[asiainfomed-blog]

Check out "Abhishek Kumar Singh Taj Pharma " on edocr.

[asiainfomed-blog]

Home

/

Press Releases

/ Global Levocetirizine Market 2016 – Auctus Pharma, Taj Group, Ultratech, Hunan Jiudian, Fuan Pharmaceutical, Shanghai Qingsong, Yongning PharmaGlobal Levocetirizine Market 2016 – Auctus Pharma, Taj Group, Ultratech, Hunan Jiudian, Fuan Pharmaceutical, Shanghai Qingsong, Yongning PharmaPosted on

January 9, 2017

by

ReleaseWire - Latest Press Releases

in

Press Releases

Conceptual image of a businessman holding big hammer

Global Levocetirizine Market Outlook 2016-2021

Deerfield Beach, FL — (SBWIRE) — 01/09/2017 — Levocetirizine (as levocetirizine dihydrochloride) is a third-generation non-sedative antihistamine, developed from the second-generation antihistamine cetirizine. Chemically, levocetirizine is the active enantiomer of cetirizine. It is the R-enantiomer of the cetirizine racemate. Levocetirizine is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells.

For sample request click on http://www.marketresearchstore.com/report/global-levocetirizine-market-outlook-2016-2021-95401#RequestSample

This report provides detailed analysis of worldwide markets for Levocetirizine from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Levocetirizine market and further lays out an analysis of the factors influencing the supply/demand for Levocetirizine, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

This report, Global Levocetirizine Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Levocetirizine market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies.

Global Levocetirizine Market : Top Manufactures Auctus Pharma (India) Taj Group (India) Ultratech (India) Hunan Jiudian (China) Fuan Pharmaceutical (China) Shanghai Qingsong (China) Yongning Pharma (China)

Have Any Query? Ask Our Expert @ http://www.marketresearchstore.com/report/global-levocetirizine-market-outlook-2016-2021-95401#InquiryForBuying

In this sector, global competitive landscape and supply/demand pattern of Compressor Impeller industry has been provided.

In this report analysis, traders and distributors analysis is given along with contact details. For material and equipment suppliers also, contact details are given. New investment feasibility analysis and Industry growth is included in the report.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-levocetirizine-market-2016-auctus-pharma-taj-group-ultratech-hunan-jiudian-fuan-pharmaceutical-shanghai-qingsong-yongning-pharma-757949.htm

Media Relations Contact

Joel John Corporate Sales Specialist Market Research Store Telephone: 386-310-3803 Email: Click to Email Joel John Web: http://www.marketresearchstore.com/report/global-levocetirizine-market-outlook-2016-2021-95401

[asiainfomed-blog]

Judgment of Novartis Glivec: Taj Pharma and Indian healthcare companies Gains in India

April 30, 2013 in Uncategorized

The Indian Supreme Court rejected the appeal of the Novartis patent protection of the updated version dell’antitumorale Glivec.

Maharashtra, Mumbai, April 9, 2013: Here are the drugmakers in pole position to win market share that Novartis is likely to yield. Following the judgment of the Indian Supreme Court, which dismissed the appeal by Novartis for patent protection of Glivec (imatinib), it is natural to ask, what are the generic companies that could take advantage of this niche market opened by this decision.

Novartis, in India, is destined to lose a share of the market share of Glivec is confirmed by the first reactions of the Stock Exchange in Mumbai, the square in which the title of the Swiss giant has immediately yielded 6.8%. It would benefit especially Taj Pharmaceuticals, a leading Indian generic manufacturer, Celon Labs, Natco Pharma, Dr. Reddy, Miracalus Pharma, Cipla, Glenmark Pharmaceuticals, Ranbaxy (a subsidiary of Daiichi Sankyo) and Shantha Biotechnics.

The Indian generics giant ‘Taj Pharma’ CEO A.K.Singh said in an interview with Bloomberg “the decision will have a positive impact on drug affordability, accessibility and availability of this drug in India for cancer (myeloid leukemia) patents, as Glivec (imatinib) costs more than Rs.10 lacks for monthly treatment compared to Rs.10,000 for our generic imatinib tablets”. Further, emphasised that life saving drugs should not be sold at “unaffordable prices” in shed of “international patent protection” and “research innovation”, when the underlying motive is revenue; human life should be considered above these motives and the Indian court decision should be considered in favour of healthcare industry to serve human race. Moreover, Singh also supports the idea of open “international patent pool” for life saving drugs as proposed in EMA Committee 2010.

On the other hand, some manufacturers of generic imatinib listed on the stock market have gained ground on the Bombay Stock Exchange, which allows you to make a fairly accurate estimate of what the companies in pole position to win market share that Glivec “designer” is intended to give in the coming months. the first place there Taj Pharma and Natco Pharma, whose stock rebounded by 9.6 and 5.4% respectively, in third place Ranbaxy, which marked a 2.7%, and in fourth place Cipla, whose title was up 1, 2% on the Bombay Stock Exchange.

Companies that already placing imatinib equivalent in India will no doubt take advantage of the comparative advantage that is to be already on the market, but this does not preclude other generics also active in other countries of the world, they decide to expand or short to converge on Indian square. In addition to Sandoz, which belongs to the same Novartis, one of the manufacturers of generic drugs in its portfolio that imatinib can be mentioned, for example, Teva and Aurobindo.

Generics, India is its voice

The case of our riflemen to the arms race, the higher specific gravity claimed within the United Nations to the historic judgment against Big Pharma. India is dragging its feet on the international stage. And it does so with a strong position of respect not only from the economic point of view, but also for major social and health issues.

The story is well known: on April 1, the Indian Supreme Court dismissed the appeal by Novartis concerning patent protection of the updated version of Gleevec , the cancer drug used for the treatment of myeloid leukemia and other cancers. The drug costs about $ 2,600 per month, while its equivalent is available for just $ 175.

For the judges, the Glivec would not be a new “invention”, but only the reformulation of the ‘ imatinib , a molecule whose patent has expired. The judgment binds to the Indian Patent Act, as amended in 2005, according to which “new version of a drug can be patented only if it is shown to be greater therapeutic efficacy than previous versions, whose patent has expired.”

THE BACKGROUND

For years India has strongly sided with the right to health, and emerging local pharmaceutical industry, earning the reputation as the “pharmacy of the poor” through a law that allowed the massive commercialization by Indian companies of generic drugs at prices much lower than the equivalent “designer”. The judgment of 1 April seems to confirm this trend.

Under international pressure, India has revised the law to patents on medicines until 2005, but the new provisions related only to the molecules discovered after 1995. Novartis had patented a version of Glivec in 1993, after abandoning the development, but the Indian judges have held, in which the first version of the drug and later versions are not “quite different”, so that the next release does not deserve an independent patent.

In particular, in the jargon is called “evergreening” the practice Indian law intellectual property rights on drugs aims to tackle: it is the subtle improvements made ​​to a drug whose patent is about to expire, in order to extend the patent protection.

The judgment against Novartis is the latest in a series of defeats suffered by similar multinational pharmaceutical companies in India. In recent months, the Indian judges have revoked the patent on several drugs giants Pfizer and Roche, as the cancer drug Tarceva, which is “copied” from the Indian Cipla, in fact undermining their monopoly. The singular story of Nexavar, an expensive drug against kidney cancer and liver produced by Bayer. A few months ago, the Court of Appeal in India has given the green light for production by the Indian generic Natco Pharma, although the drug was still under patent. A decision on the grounds that the drug “was not accessible to the majority of patients.” In fact, the Indian judges have forced Bayer to grant the license to produce the drug in exchange for 6 percent of royalties. Bayer did not appreciate the judgment and has already been used.

REACTIONS

The Basel pharmaceutical giant said the decision will have a negative impact on research and innovation in India, a country which “refuses to protect the patent for Glivec, although the drug is recognized worldwide and protected in almost forty states,” says Novartis said in a statement. Signal opposite reactions NGO Berne Declaration and Doctors Without Borders, according to which the judgment Glivec represents a significant victory for patients who live in the poorest countries on the planet.

Interviewed by Panorama.it, Assogenerici reserves the right to read the reasons for judgment before taking a position on the matter. Instead, according to Massimo Scaccabarozzi, a number of Farmindustria , “the judgment deteriorates kills innovation and research.” He adds: “For a molecule steps by the discovery, which is when you registered the patent, trade spend ten years. The coverage lasts for twenty years, but not from the entrance on the market, so it is already halved. Reduce it further means killing research. ”

HOW MUCH IS THE DRUG MARKET

The study “Global Pharmaceutical market report & forecast: 2012-2017” , illustrates that the current pharmaceutical market amounted to almost 900 billion dollars a year but is expected to grow in the next five years at a rate of 5 per cent per annum and, in 2017, will amount to at least 1.1 trillion dollars. However, the demand for drugs will grow especially in emerging economies, whose incidence in the world market could increase from 15 to 30 percent. This is also due to the patent protection of many drugs worth $ 29 billion in 2013 and $ 40 billion in 2014. Most of the market for these brand-name drugs will be replaced with generic drugs, a significantly lower cost.

According to the newspaper “The Unit”, between 2005 and 2020, the FDA, the U.S. organization responsible to monitoring of drugs, authorized the sale of only 22 new drugs a year. The industries are struggling to innovate and seek to extend the patent expired in older drugs ritoccandoli in non-essential components.

Each new drug then loses value. The “golden age”, every new drug in five years hits the placing on the market produced $ 515 million, it now produces 430: a net loss of 15 per cent. And again, the companies in the first 5 years after the development of a new drug ricavavano $ 275 million for every billion dollars invested in research and development. Now we derive just 75 million. Loss of productivity is 70 percent. All the more serious when you consider that global investments in “research and development” on drugs has doubled in absolute terms, dropping from 65 to 125 billion dollars.

BENEFIT FROM THE JUDGMENT?

Thanks to India’s patent law, which since 1970 allowed India to produce generic versions of drugs still under patent abroad, the Indian pharmaceutical industry has become, with that of Brazil, the largest producer of generic drugs. This has led to significant benefits especially for the poorest countries in the world, where the cost of some therapies have been literally destroyed.

According to estimates by Doctors Without Borders, for example, thanks to antiretroviral Indians and the decision of the Brazilian government to produce generic drugs for AIDS, since 2000 the price of medicines against HIV fell by 99 percent, if in 2000 treating an AIDS patient with drugs “brand” was listed at $ 10,000 a year, now the cost of the same treatment with generics produced in India is 120 dollars a year.

Following the judgment of the Indian Supreme Court is natural to ask what are the generics that could take advantage of niche opened by this decision. As reported by the Indian analysts at Bloomberg, it would benefit especially Taj Pharmaceuticals, a leading Indian generic manufacturer among others like Celon Labs, Natco Pharma, Dr. Reddy, Cipla, Glenmark Pharmaceuticals and Ranbaxy.

Some manufacturers of generic imatinib listed on the stock market have gained ground on the Bombay Stock Exchange, which allows you to make a fairly accurate estimate of what the companies in pole position to win market share that Glivec “designer” is intended to surrender in the coming months. In the first place there Natco Pharma, whose title is rebounded by 5.4 per cent in second place Ranbaxy, who scored a +2.7 per cent in third place Cipla, whose stock rose 1 , 2 percent.

This does not preclude other generics, active in other countries of the world, they decide to expand or short to converge on the square in India. In addition to Sandoz, which belongs to the same Novartis, one of the generic drug manufacturers who have imatinib in its portfolio there are Teva and Aurobindo.

THE EFFECTS IN ITALY

According to the WHO, cancer costs the EU countries 124 billion each year. But only 36 percent of the figure is related to medications, hospitalizations, interventions and therapies. Some estimates say that a cancer patient can use the total resources ranging from 50-70 thousand up to 300 thousand euro, taking into consideration in the calculation of the set of diagnoses, hospitalizations, interventions, medications and treatments.

If we take into account an average of 150 thousand euro and to multiply to one million patients in Italy, we spend 150 billion euro for a generation of patients, spread over three to five years average survival.

Figures for the most part the responsibility of the National Health System, which through exemptions, guarantees access in Italy mostly without disbursements to anti-tumor effects. At least up to now, but the crisis is felt and spaces of gratuity is reduced for patients.

Even in Italy there are generic drugs against cancer. The first was launched in 2004 and contained paclitaxel molecule used for the treatment of cancer of the breast and ovaie.L ‘incidence of low cost, however, is still a minority if you think that, overall, these drugs account for about 16 per percent of the domestic market and 8 percent of spending, public and private annual savings of about 300 million euro for the benefit of the NHS. The economic relief is crucial if one considers that the average reduction in price of 60 per cent after the expiry of patents. From New Delhi could get a decisive help.

Notes to Editor

About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world.

About EMA The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

Food and Drug Administration The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

About Taj Pharmaceuticals Group (India) Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufactures pharmaceutical formulations and API for India and other countries, owning about 450 brands and 4000 generic licenses. The company was established in 1995 as an enterprise and in 2004 became a public limited company with about $1Bn in sales.

Responsibility Statement Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts and statements that refer or relate to events or circumstances that the mentioned companies “estimates,” “believes,” or “expects” to happen or similar language. The forward-looking statements in this press release are based on the current expectations of the parties engaged and are made only as of the date of this press release and involve certain risks and uncertainties that could cause actual results to differ materially from future results that may be expressed or implied by such forward-looking statements. Unless required by law, no mentioned company undertake any obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

RATE THIS:SHARE THIS:

[asiainfomed-blog]

AstraZeneca, Taj Pharma launch Gemcitabine HCI for Injection in US

Posted Atdrugdiscovery.pharmaceutical-business-review.com

AstraZeneca Pharmaceuticals and Taj Pharmaceuticals, an India-based manufacturer of generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, have commercially launched Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials in the US.

Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, was launched pursuant to a commercialization, manufacture and supply agreement signed by AstraZeneca and Taj Pharmaceuticals, indiacompanynews.com reported.

As per the agreement, AstraZeneca will manufacture Gemcitabine HCI for Injection and will receive a license to market the product within the India-based firm's 180-day exclusivity.

Taj Pharma will get a royalty during the manufacturing period.

Indiacompanynews.com has quoted Taj Pharmaceuticals Generics senior vice president Ajay Sodhi sa saying that the agreement allows them to accelerate the availability of the important generic product Gemcitabine HCI.

Feb 08, 2011

[asiainfomed-blog]

Global Morphine Sulfate Market-Macfarlan Smith, Cepia-Sanofi, Alcaliber, SUN PHARMA

Market.Biz Leading Research Firm has added latest report on "Global Morphine Sulfate Market by Manufacturers, Regions, Type and Application, Forecast to 2021".

By

Socorro Barner

-January 10, 2017

03

Share on Facebook

Tweet on Twitter

The Morphine Sulfate market report covers forecast and analysis for the Morphine Sulfate market on a global and regional level. The Morphine Sulfate industry report provides historic data of 2015 along with a Morphine Sulfate market forecast from 2015 to 2021 based on Morphine Sulfate industry volume and Morphine Sulfate revenue (USD Million). The Morphine Sulfate includes drivers and restraints for the Morphine Sulfate market along with the impact they have on the demand over the forecast period. Additionally, the Morphine Sulfate market report includes the study of opportunities available in the Morphine Sulfate market on a global level.

The Morphine Sulfate market report discusses in details about the vendor landscape of the Morphine Sulfate market. The Morphine Sulfate Industry has been analyzed on the basis of Morphine Sulfate market attractiveness and investment feasibility. The Morphine Sulfate report lists the key players in the Morphine Sulfate market and provides crucial information about them such as business overview, revenue segmentation, and product offerings. Through SWOT analysis, the Morphine Sulfate industry report analyses the Morphine Sulfate market growth of the key players during the forecast horizon.

In Morphine Sulfate Market report, all the segments have been analyzed based on present and Morphine Sulfate market future trends and the Morphine Sulfate market is estimated from 2015 to 2021. In this Morphine Sulfate report, regional segmentation covers the Morphine Sulfate industry current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Do Inquiry Before Accessing Report Here: https://market.biz/report/global-morphine-sulfate-market-gir/29695/#inquiry

This report segments the global Morphine Sulfate industry as follows:

Global Morphine Sulfate Market: Manufacturers Segment Analysis 1. Taj Pharmaceuticals 2. SUN PHARMA 3. Qinghai Pharmaceutical 4. Purdue Pharma 5. Northeast Pharm 6. Mallinckrodt Pharmaceuticals 7. Macfarlan Smith 8. Cepia-Sanofi 9. Alcaliber Global Morphine Sulfate Market: Applications Segment Analysis 1. Oral Tablets 2. Injection 3. Capsule 4. Others Global Morphine Sulfate Market: Regional Segment Analysis 1. North America (USA, Canada and Mexico) 2. Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 3. Europe (Germany, France, UK, Russia and Italy) 4. South America, Middle East and Africa

Get Instant Access To the Full Report with TOC at https://market.biz/report/global-morphine-sulfate-market-gir/29695/

Report on (Global study on Morphine Sulfate industry) mainly covers 13 Chapters to deeply display the global Morphine Sulfate market.

Chapter I, to explain Morphine Sulfate market Intro, product extent, market summary, market opportunities, market threat, market driving force;

Chapter II, to examine the top manufacturers of Morphine Sulfate market, with sales, revenue, as well as price of Morphine Sulfate, in 2015 and also 2016;

Chapter III, to display the Morphine Sulfate market’s affordable circumstance amongst the top key players, with sales, Morphine Sulfate market revenue and share in 2015 and also 2016;

Chapter IV, to reveal the worldwide Morphine Sulfate market by areas, with sales, revenue and market share of Morphine Sulfate, for each region, from 2011 to 2016;

Chapter V, VI, VII & VIII, to analyze the key regions of Morphine Sulfate market, with sales, revenue and also market share by manufacturers countries in these regions;

Chapter IX and X, to reveal the Morphine Sulfate market by type as well as application, with sales Morphine Sulfate market share as well as growth price by type, application, from 2011 to 2016;

Chapter XI, Global Morphine Sulfate market forecast, by regions, type and also application, with sales as well as revenue, from 2016 to 2021;

Chapter XII and also XIII, to describe Morphine Sulfate market sales network, suppliers, investors, suppliers, appendix and also data resource.

Browse More Related Category Research Reports at: https://market.biz/reporttype/pharmaceuticals-and-healthcare/

TAGS

Global Morphine Sulfate Market

SHARE

Facebook

Twitter

[asiainfomed-blog]

Codeine is an opiate used to treat pain, as a cough medicine, and for diarrhea.[2][3] It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen.[2] Evidence does not support its use for acute cough suppression in children or adults.[4][5] In Europe it is not recommended as a cough medicine in those under twelve years of age. It is generally taken by mouth. It typically starts working after half an hour with maximum effect at two hours. The total duration of its effects last for about four to six hours.[2]

Common side effects include vomiting, constipation, itchiness, and lightheadedness. Serious side effects may include breathing difficulties and addiction. It is unclear if its use in pregnancy is safe. Care should be used during breastfeeding as it may result in opiate toxicity in the baby.[2] Its use as of 2016 is not recommended in children.[6] Codeine works following being broken down by the liver into morphine. How quickly this occurs depends on a person's genetics.[2]

Codeine was discovered in 1832 by Pierre Jean Robiquet.[7] In 2013 about 361,000 kilograms of codeine were produced while 249,000 kilograms were used. This makes it the most commonly taken opiate.[8] It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.[9] The wholesale cost in the developing world is between 0.04 and 0.29 USD per dose as of 2014.[10] In the United States it costs about one dollar a dose.[2] Codeine occurs naturally and makes up about 2% of opium.[7]

[asiainfomed-blog]

Wikipedia Taj Pharmaceuticals

Taj PharmaceuticalsFrom Wikipedia the free encyclopedia

Crown PharmacyTaj Pharmaceuticals

type

public company

Udmog

Pharmaceuticals

the establishment1995

Headquarters

Mumbai

,

Maharashtra

,

India

[1]

Key peopleDR. RK Singh, Chairman

[1]

,

Abhishek Kumar Singh

, chief executive officer

[2]

ProductPharmaceuticals, bulk drugs and Chemicals

[3]

Website[Wwwktajpharmakcom]

Taj Pharmaceuticals (Taj Pharma India) Group, an Indian pharmaceuticals drugs, active pharmaceutical ingredients and chemicals involved in the manufacturing group. The group's main business is mainly in two key areas, generics and bulk drugs in the health care field worldwide leading specialty chemicals with offering contract manufacturing. [Iv][iii][vi][vi]

History [ edit ]

The company in 1995 in Mumbai, India was included with the headquarters. Taj Pharma Group largest generics and active ingredients with a market capitalization of 1.7 billion is said to be one of manufacturing. In early 2011 the group £ 80 million loss in the fourth quarter due to heavy legal law a share buyback notice Diksmuh AstraZeneca UK in 2011 with gemcitabine HCl injection in the United States launched. Also in the group with the corporate fund pharmaceuticals giant GlaxoSmithKline and Eli Lilly supported the spin-out of the fund.

References [ edit ]

↑ A's"Taj Pharmaceuticals Ltd. - Annual Report, 2009" . Retrieved 2011-12-15.

↑ Actiteepi://wwwkindiacompanynewskcom/post/wu/3756/ni-chif-agjikyutiv-afsr-ofa-taj-farmasyutikals-grup/

↑ Thecoming Akhil H. Kholi. "Financial results for the quarter (Q3) ended 31st December, 2010" . . Retrieved 2011-12-15.References Error: Invalid <ref> tag; The name "Pres_riliz" defined multiple times with Different Content

↑ "Taj Pharma India" . Actiteepi://wwwkmoneycontrolkcom/nuz-topik/veedio-taj-frm-india . Retrieved 2011-12-15.

↑ "Taj Pharmaceuticals French TV Interview - Channel TF1 France" (in french). . Retrieved 2010-09-30.

↑ "If Fd APPROVALS & Notes Editor" . . Retrieved 2011-12-15.

External links [ edit ]

[Wwwktajpharmakcom Home page]

Customers were pharmacists - 2008 - page five - Ginmeno-Plus (Taj Pharmaceuticals)

EU-Indonesia Business Dialogue (Aebd) - page seventeen

Category

:

With reference to the error page

[asiainfomed-blog]

ताज फार्मास्यूटिकल्समुक्त ज्ञानकोश विकिपीडिया से

ताज फार्मेसीताज फार्मास्यूटिकल्स

प्रकार

सार्वजनिक कंपनी

उद्मोग

फार्मास्यूटिकल्स

स्थापना1995

मुख्यालय

मुंबई

,

महाराष्ट्रा

,

भारत

[1]

प्रमुख व्यक्तिडॉ॰ आर के सिंह, अध्यक्ष

[1]

,

अभिषेक कुमार सिंह

, मुख्य कार्यकारी अधिकारी

[2]

उत्पादफार्मास्यूटिकल्स, बल्क ड्रग्स एंड केमिकल्स

[3]

वेबसाइट[www.tajpharma.com]

ताज फार्मास्यूटिकल्स (ताज फार्मा इंडिया) समूह, एक भारतीय फार्मास्यूटिकल्स दवाओं, सक्रिय दवाइयों सामग्री और रसायनों के निर्माण में शामिल समूह है। समूह के मुख्य व्यवसाय के दो प्रमुख क्षेत्रों में मुख्य रूप से है, जेनरिक बल्क ड्रग्स और विशेषता रसायनों दुनिया भर में प्रमुख स्वास्थ्य देखभाल के क्षेत्र में की पेशकश के साथ अनुबंध विनिर्माण.[4][3][5][6]

इतिहास[संपादित करें]

कंपनी 1995 में मुंबई, भारत में मुख्यालय के साथ शामिल किया गया था। ताज फार्मा समूह सबसे बड़ी जेनरिक और सक्रिय सामग्री 1,7 अरब बाजार पूंजीकरण के साथ विनिर्माण में से एक होने के लिए कहा है। हालांकि समूह £ 80 मिलियन 2011 के शुरू में भारी कानूनी कानून पर चौथी तिमाही में घाटा दर्ज की वजह से एक शेयर वापस खरीदने की सूचना दी.समूह 2011 में gemcitabine एस्ट्राज़ेनेका ब्रिटेन के साथ संयुक्त राज्य अमेरिका में एचसीएल इंजेक्शन का शुभारंभ किया। इसके अलावा समूह कॉर्पोरेट निधि साथ में फार्मास्यूटिकल्स दिग्गज ग्लैक्सोस्मिथक्लाइन और एली लिली के साथ स्पिन के बाहर निधि का समर्थन किया।

संदर्भ[संपादित करें]

↑ इस तक ऊपर जायें:अआ"Taj Pharmaceuticals Ltd. - Annual Report, 2009". अभिगमन तिथि: 2011-12-15.

ऊपर जायें↑ http://www.indiacompanynews.com/post/view/3756/New-chief-executive-officer-of-Taj-Pharmaceuticals-Group/

↑ इस तक ऊपर जायें:अआ Akhil H. Kholi. "Financial results for the quarter (Q3) ended 31st December, 2010". Indiaprwire.com. अभिगमन तिथि: 2011-12-15. सन्दर्भ त्रुटि: Invalid <ref> tag; name "press_release" defined multiple times with different content

ऊपर जायें↑ "Taj Pharma India". http://www.moneycontrol.com/news-topic/video-taj-pharma-india. अभिगमन तिथि: 2011-12-15.

ऊपर जायें↑ "Taj Pharmaceuticals French TV Interview - Channel TF1 France" (french में). youtube.com. अभिगमन तिथि: 2010-09-30.

ऊपर जायें↑ "FDA Approvals & Notes to Editor". Pr4india.com. अभिगमन तिथि: 2011-12-15.

बाहरी लिंक[संपादित करें]

[www.tajpharma.com Home page]

The Pharmacist Book - 2008 - Page 5 - GYNAMENO-PLUS (Taj Pharmaceuticals)

EU-Indonesia Business Dialogue (EIBD) - Page 17